- Vifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant patients at risk for delayed graft function
admin Wed, 10/27/2021 - 16:46
Vifor Pharma andAngion Biomedica Corp announced that the phase-III trial of Angion’s ANG-3777 did not demonstrate a statistically significant difference from placebo on the primary endpoint (eGFR at 12 months) in the population of deceased donor kidney transplant patients who were at risk for developing DGF.
- Silver Bullet Therapeutics Launches OrthoFuzIon Bone Screw System
admin Mon, 10/25/2021 - 15:56
Silver Bullet Therapeutics, Inc a privately-held medical device company, announced today that it is formally launching its antimicrobial OrthoFuzIon Bone Screw System at the DKOU German Congress of Orthopedics and Traumatology on October 26-29 in Berlin.
Silver Bullet Therapeutics OrthoFuzIon product line will be featured at the Argomedical booth at Nr. 61 in Hall 4.2.
- Roche launches comprehensive genomic profiling kit
admin Mon, 10/25/2021 - 15:50
Roche announced that it has launched the AVENIO Tumor Tissue CGP Kit. The Kit complements the current CGP portfolio offered by Roche and Foundation Medicine and allows laboratories to expand their oncology research in-house. Ultimately, a future version of the kit may lead to additional resources for clinicians to use in the diagnosis and treatment of cancer.
- CANOPY-1 Phase III study did not demonstrate the statistically significant primary endpoints
admin Mon, 10/25/2021 - 15:41
Novartis announced that the CANOPY-1 Phase III study did not demonstrate the statistically significant primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients treated with canakinumab (ACZ885) combined with pembrolizumab plus platinum-based doublet chemotherapy, compared to patients receiving placebo in combination with pembrolizumab plus platinum-based doublet chemotherapy.
- Advanced Radiation Therapy, LLC and Apollo Healthcare Announce Strategic Partnership
admin Sat, 10/23/2021 - 16:10
Advanced Radiation Therapy, LLC (ART) and Apollo Healthcare have today announced a strategic partnership aimed at easing the challenge radiation oncology clinics have in pre-authorizing patients for insurance coverage for innovative radiation cancer therapies.
- FDA approves Susvimo for macular degeneration
admin Sat, 10/23/2021 - 16:03
Roche announced that the U.S. Food and Drug Administration (FDA) has approved Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with neovascular or wet age-related macular degeneration (nAMD) who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. Neovascular AMD is a potentially blinding condition that requires treatment with eye injections as often as once a month.
- Aino Health is approved by Swedish Social Insurance Agency as a workplace-oriented rehabilitation support organizer
admin Fri, 10/22/2021 - 16:00
Swedish Social Insurance Agency (Försäkringskassan), has granted Aino Health approval to provide proactive and rehabilitative efforts in the workplace. In collaboration with Swedish Social Insurance Agency, Aino Health can offer support investigating, planning, implementing and following up on work-oriented measures.
The purpose of the grant is to prevent sick leave and make it easier for employees to return to work after sick leave.
- Dupixent (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease
admin Fri, 10/22/2021 - 15:47
PARIS and TARRYTOWN, N.Y. – October 22, 2021 - A pivotal Phase 3 trial evaluating Dupixent® (dupilumab) in adults with uncontrolled prurigo nodularis, a chronic type 2 inflammatory skin disease that causes extreme itch and skin lesions, met its primary and all key secondary endpoints, showing that Dupixent significantly reduced itch and skin lesions compared to placebo in this investigational setting. The impact of uncontrolled prurigo nodularis on quality of life is one of the highest among inflammatory skin diseases with intense, chronic itch.
- LumiraDx receives approval for its COVID-19 Antigen Test for use in India
admin Thu, 10/21/2021 - 16:16
LumiraDx a next-generation point of care diagnostics testing company announced it has received emergency use approval by India’s Central Drugs Standard Control Organisation for its SARS-CoV-2 Antigen test for use in India. The test detects antigen nucleocapsid protein from a nasal swab with results in under 12 minutes from sample application.
- Amgen Successfully Completes Acquisition Of Teneobio, Inc
admin Thu, 10/21/2021 - 16:11
Amgen announced that it has successfully completed its previously announced acquisition of Teneobio, Inc. (Teneobio). Effective as of Oct. 19, 2021, Amgen has acquired all outstanding equity of Teneobio in exchange for a $900 million upfront cash payment, as well as future contingent milestone payments, to former Teneobio equity holders potentially worth up to an additional $1.6 billion in cash.